Navigation Links
VirtualScopics, Inc. Schedules Second Quarter 2014 Financial Results Press Release, Conference Call And Webcast
Date:8/5/2014

ROCHESTER, N.Y., Aug. 5, 2014 /PRNewswire/ -- VirtualScopics, Inc. (NASDAQ: VSCP), a leading provider of clinical trial imaging solutions, today announced it will report its second quarter and six months 2014 financial results before the market opens on Thursday, August 14, 2014.  Eric T. Converse, president and chief executive officer, and Jim Groff, acting chief financial officer, will host a conference call and webcast to discuss the company's financial results and provide a business update at 8:30 a.m. ET that morning.  Conference call, webcast and replay information is as follows:Domestic Call Dial In:  877-407-8035International Call Dial In:  201-689-8035Conference Call ID:  13587794An accompanying slide presentation to enhance managements' formal remarks, as well as a webcast of the call, can be accessed at: www.virtualscopics.com or at: http://www.investorcalendar.com/IC/CEPage.asp?ID=173036.

A replay and slide presentation will be available one hour after the conclusion of the conference call for 90 days, and can be accessed accordingly:Replay Domestic Dial In:  877-660-6853Replay International Dial In:  201-612-7415Replay Conference Call ID:  13587794Webcast and slide presentation can be accessed at:  www.virtualscopics.com or at: http://www.investorcalendar.com/IC/CEPage.asp?ID=173036.

About VirtualScopics, Inc.
VirtualScopics, Inc. (NASDAQ: VSCP) is a leading provider of clinical trial imaging solutions to accelerate drug and medical device development.  For risk-averse, time-constrained Clinical Trial Study Teams, Medical Directors and Imaging Scientists who require quality imaging data delivered on-time, within budget and on a consistent basis, VirtualScopics' clinical trial imaging solutions are an inspired true exception to commonly accepted services provided by other clinical trial imaging providers.  Because of the scientific and operational flexibility and responsiveness they can offer, VirtualScopics' clinical trial imaging solutions deliver special performance advantages compared to other image service providers that offer common, every day clinical trial imaging services.  For more information about VirtualScopics, Inc. please visit www.virtualscopics.com.

Forward-looking Statements
The statements contained in this press release that are not purely historical are forward-looking Statements within the meaning of Section 27Aof the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby.  These forward-looking statements include, but are not limited to, statements regarding the expected benefits of the Company's investment in infrastructure, the strategic alliance with IXICO plc  and new customer contract signings and awards and/or statements preceded by, followed by or that include the words "believes," "could," "expects," "anticipates," "estimates," "intends," "plans," "projects," "seeks," or similar expressions.  Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations.  Investors are cautioned that all forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements.  Many of these risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2013 filed with the Securities and Exchange Commission (the "SEC"), and in any subsequent reports filed with the SEC, all of which are available at the SEC's website at www.sec.gov.  These include without limitation:  the risk of cancellation or delay of customer contracts or specifically as it relates to contract awards, the risk that they may not get signed.  Other risks include the Company's dependence on its largest customers and risks of contract performance, protection of our intellectual property and the risks of infringement of the intellectual property rights of others.  All forward-looking statements speak only as of the date of this press release and the Company undertakes no obligation to update such forward-looking statements.

For More Information, Contact:
Donna N. Stein, APR, Fellow PRSA
Managing Partner
Donna Stein & Partners
315-361-4672
Email:  dstein1@twcny.rr.com


'/>"/>
SOURCE VirtualScopics, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman
2. Eric T. Converse Named President And Chief Executive Officer Of VirtualScopics, Inc.
3. Thoratec Schedules First Quarter Conference Call, Webcast
4. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
5. Heartware Schedules First Quarter Conference Call And Webcast
6. Ampio Pharmaceuticals Schedules 2012 Update Webcast
7. China Botanic Schedules Conference Call to Discuss Second Quarter Fiscal Year 2012 Results
8. Mylan Schedules Second Quarter 2012 Financial Results Conference Call and Live Webcast
9. Sinovac Schedules 2012 Annual Meeting of Shareholders
10. 3SBio Inc. Schedules Unaudited Second Quarter 2012 Results
11. Volcano Corporation Schedules Second Quarter Conference Call, Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Spiral Therapeutics, Inc. today announced ... Farma, S.L. for the worldwide exclusive rights to ... the field of otolaryngology for aggregate payments of ... The agreement provides Spiral with the option to ... product profile. Under the terms of the agreement, ...
(Date:3/29/2017)... 2017 NetworkNewsWire Editorial Coverage  ... There are a ... regulating marijuana, but economic arguments also favor its legalization. The ... enforcement costs. However, to legalize and regulate marijuana requires an ... (OTC: SING) ( SING Profile ), American Cannabis Company (OTC: ...
(Date:3/29/2017)... NEW YORK , March 29, 2017 ... ... cannabis market. According to a new report published by New Frontier ... by 2020. The accelerating pace of cannabis legalization in ... of legalizing cannabis, are considered to be a major factor that ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... March 29, 2017 , ... The assembly of synthetic DNA ... many repetitive steps and often scientists require many different versions of DNA. Therefore, ... results in a lower error rate and cost saving for reagents and consumables. ...
(Date:3/29/2017)... , ... March 29, 2017 ... ... and South Hills of Pittsburgh now have easier access to the robotic-assisted ... by Allegheny Health Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson ...
(Date:3/29/2017)... ... March 29, 2017 , ... AvePoint , the ... American office location in Richmond, Virginia, located at the Riverfront Plaza, 901 East Byrd ... Lieutenant Governor of Virginia Ralph S. Northam and Mayor of Richmond Levar M. Stoney. ...
(Date:3/28/2017)... , ... March 28, 2017 , ... Tuesday, March 28, ... American public to take the Diabetes Risk Test to find out if they are ... Angeles World Airports will light up the evening sky by programming the LAX pylons ...
(Date:3/28/2017)... SEATTLE, Washington and CARTERSVILLE, Georgia (PRWEB) , ... ... ... adding another senior analyst to its award-winning team. Ruel Williamson brings his extensive ... Advisors, which has been a leader in the real estate valuation industry for ...
Breaking Medicine News(10 mins):